1112 ET - BioNTech expects its Covid-19 booster sales to stay relatively stable even if the government narrows its recommendations of who needs the shot. The Centers for Disease Control is scheduled to vote in June on a new recommendation for who should get the Covid-19 booster, which could narrow it to high-risk groups only. BioNTech, which rose to prominence for its partnership with Pfizer during the Covid-19 pandemic, says during an analyst call that many of the people still getting the booster are in high-risk groups already. The majority of Covid vaccines in the U.S. are going to people who are older than 65 or immunocompromised, which accounts for about 20% of Americans, management says. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

May 05, 2025 11:13 ET (15:13 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.